Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7912735rdf:typepubmed:Citationlld:pubmed
pubmed-article:7912735lifeskim:mentionsumls-concept:C0035647lld:lifeskim
pubmed-article:7912735lifeskim:mentionsumls-concept:C0439849lld:lifeskim
pubmed-article:7912735lifeskim:mentionsumls-concept:C0040616lld:lifeskim
pubmed-article:7912735lifeskim:mentionsumls-concept:C0379900lld:lifeskim
pubmed-article:7912735lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:7912735lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:7912735lifeskim:mentionsumls-concept:C1621296lld:lifeskim
pubmed-article:7912735lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:7912735lifeskim:mentionsumls-concept:C0256629lld:lifeskim
pubmed-article:7912735lifeskim:mentionsumls-concept:C0243072lld:lifeskim
pubmed-article:7912735pubmed:issue12lld:pubmed
pubmed-article:7912735pubmed:dateCreated1994-8-3lld:pubmed
pubmed-article:7912735pubmed:abstractTextA series of 3,4-dihydro-3-amino-2H-1-benzopyran derivatives were prepared in order to determine the necessary structural requirements for good affinity for 5-HT1A receptors and high selectivity versus other receptors. Modifications of the extracyclic amino substituents, the length of the alkyl side chains, and their substituents were explored. The best compounds (9g, 9k, 15b, 15d) possess imido or sulfonamido functional groups with a preferential length of four methylenes for the side chain. After resolution, the dextrorotatory enantiomers showed better affinity and selectivity for 5-HT1A receptors. These compounds have been proven to be full agonists. 9g and its enantiomers showed anxiolytic activity in vivo in various comportemental models. The compound (+)-9g is currently under clinical investigation.lld:pubmed
pubmed-article:7912735pubmed:languageenglld:pubmed
pubmed-article:7912735pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7912735pubmed:citationSubsetIMlld:pubmed
pubmed-article:7912735pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7912735pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7912735pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7912735pubmed:statusMEDLINElld:pubmed
pubmed-article:7912735pubmed:monthJunlld:pubmed
pubmed-article:7912735pubmed:issn0022-2623lld:pubmed
pubmed-article:7912735pubmed:authorpubmed-author:AdamGGlld:pubmed
pubmed-article:7912735pubmed:authorpubmed-author:PfeifferBBlld:pubmed
pubmed-article:7912735pubmed:authorpubmed-author:RenardPPlld:pubmed
pubmed-article:7912735pubmed:authorpubmed-author:GuillaumetGGlld:pubmed
pubmed-article:7912735pubmed:authorpubmed-author:CaignardD HDHlld:pubmed
pubmed-article:7912735pubmed:authorpubmed-author:Guardiola-Lem...lld:pubmed
pubmed-article:7912735pubmed:authorpubmed-author:PodonaTTlld:pubmed
pubmed-article:7912735pubmed:issnTypePrintlld:pubmed
pubmed-article:7912735pubmed:day10lld:pubmed
pubmed-article:7912735pubmed:volume37lld:pubmed
pubmed-article:7912735pubmed:ownerNLMlld:pubmed
pubmed-article:7912735pubmed:authorsCompleteYlld:pubmed
pubmed-article:7912735pubmed:pagination1779-93lld:pubmed
pubmed-article:7912735pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:7912735pubmed:meshHeadingpubmed-meshheading:7912735-...lld:pubmed
pubmed-article:7912735pubmed:meshHeadingpubmed-meshheading:7912735-...lld:pubmed
pubmed-article:7912735pubmed:meshHeadingpubmed-meshheading:7912735-...lld:pubmed
pubmed-article:7912735pubmed:meshHeadingpubmed-meshheading:7912735-...lld:pubmed
pubmed-article:7912735pubmed:meshHeadingpubmed-meshheading:7912735-...lld:pubmed
pubmed-article:7912735pubmed:meshHeadingpubmed-meshheading:7912735-...lld:pubmed
pubmed-article:7912735pubmed:meshHeadingpubmed-meshheading:7912735-...lld:pubmed
pubmed-article:7912735pubmed:meshHeadingpubmed-meshheading:7912735-...lld:pubmed
pubmed-article:7912735pubmed:meshHeadingpubmed-meshheading:7912735-...lld:pubmed
pubmed-article:7912735pubmed:meshHeadingpubmed-meshheading:7912735-...lld:pubmed
pubmed-article:7912735pubmed:meshHeadingpubmed-meshheading:7912735-...lld:pubmed
pubmed-article:7912735pubmed:year1994lld:pubmed
pubmed-article:7912735pubmed:articleTitle3,4-Dihydro-3-amino-2H-1-benzopyran derivatives as 5-HT1A receptor ligands and potential anxiolytic agents. 1. Synthesis and structure--activity relationship studies.lld:pubmed
pubmed-article:7912735pubmed:affiliationLaboratoire de Chimie Bioorganique et Analytique, associé au CNRS, Université d'Orléans, France.lld:pubmed
pubmed-article:7912735pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7912735pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:7912735lld:chembl